Abbott gets US nod for DES (drug-eluting stent) trial
This article was originally published in Clinica
Executive Summary
The US FDA has given Abbott conditional approval to begin a 1,670-patient, multicentre trial of its drug-eluting stent (DES), ZoMaxx.